Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | ACACB | O00763 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5991151 | 0.87 | MAPK1 (0.35) | RAB9AHTTSMN1; SMN2ALDH1A1POLB | |
| SCHEMBL5952260 | 0.80 | RAB9A (0.37) | RAB9AACACB | |
| SCHEMBL26319748 | 0.78 | RAB9A (0.48) | RAB9ATSHRHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL5990752 | 0.77 | GPR119 (0.36) | SMN1; SMN2GAAKMT2A | |
| SCHEMBL26319747 | 0.74 | RAB9A (0.55) | RAB9ATSHRHTTALDH1A1GAA | |
| SCHEMBL13014741 | 0.74 | KCNH2 (0.41) | ELANE | |
| SCHEMBL13062409 | 0.74 | ALDH1A1 (0.38) | RAB9ASMN1; SMN2ALDH1A1KMT2APOLB | |
| SCHEMBL13014771 | 0.74 | GPR119 (0.35) | — | |
| SCHEMBL30934674 | 0.73 | CTSL (0.41) | TSHRSMN1; SMN2PKMMAPK1ACACB | |
| SCHEMBL34474113 | 0.73 | SMN1; SMN2 (0.57) | SMN1; SMN2ALDH1A1KMT2APOLBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9278922-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-20100317568-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2010-12-16 | — | — | US | disclosed |
| US-20100267634-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317568-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | RAB9A 1535/4885TSHR 4834/4885HTT 1821/4885 |
| US-20100267634-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | RAB9A 1535/4885TSHR 4834/4885HTT 1821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.